Company: STAA
Filing Date: 2025-10-07
Form Type: PX14A6G
Source: 0001193125-25-232531
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-10-07
Form: PX14A6G
Chunk 3
---
 Claims

STAAR’s recent presentation claims that“STAAR has overweight exposure to China, where growth has slowed and macroeconomic conditions, new market entrants, and the resultingpotential for pricing pressure are creating greater risks and headwinds.” (STAAR Investor Presentation, page 6)

STAAR’s presentation inaccurately portrays STAAR’s China exposure as a liability. Based on our analysis and experience, STAAR’s strong
position in China is a core competitive advantage.

China’s expanding middle class supports a favorable outlook for ICL procedures. Since its
initial launch, STAAR has consistently gained share against laser-based alternatives through effective education of the medical community and consumers on ICL benefits.

While China’s economy recently experienced cyclical softness – with GDP growth dipping to 4.7% and 4.6% in the second and third quarters of 2024,
respectively – it has since recovered and achieved 5.4% and 5.2% growth in the first and second quarters of 2025, respectively. We also understand from our research that STAAR successfully implemented a 5% price increase in China for ICL units
as recently as 2023, demonstrating pricing power. Additional unit economics upside is anticipated with the introduction of the ICL v5 (EVO+), which received regulatory approval in China mid-2025. Similar to
the surge observed in the summer of 2023 as the market rebounded from COVID, pent-up patient demand is likely building in anticipation of this enhanced product.

As Broadwood Partners called out in its presentation, STAAR expressed in the very recent past similar optimism about its competitive position, sales outlook
and the improvement of China’s macroeconomic environment, contradicting what the Company expressed in its latest investor presentation advocating for the proposed merger.

EVO ICLs Can Penetrate the Market Beyond High Myopia Patients, Despite STAAR’s Most Recent Claims

STAAR’s recent presentation claims that“While EVO ICLs can be used across varying levels of myopia severity, in the 10+ years since launch, STAAR has not been able to penetrate the market beyond high myopia patients.” (STAAR Investor Presentation, page 6)

This claim is not
supported by the facts. At the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (with the American Society of Ophthalmic Administrators) held April 25-28, 2025, at the Los Angeles
Convention Center